RAPT Therapeutics (RAPT) Cash & Equivalents (2020 - 2024)
Historic Cash & Equivalents for Therapeutics (RAPT) over the last 5 years, with Q3 2024 value amounting to $37.9 million.
- Therapeutics' Cash & Equivalents fell 2998.98% to $37.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was $37.9 million, marking a year-over-year decrease of 2998.98%. This contributed to the annual value of $47.5 million for FY2023, which is 2190.73% up from last year.
- Latest data reveals that Therapeutics reported Cash & Equivalents of $37.9 million as of Q3 2024, which was down 2998.98% from $37.1 million recorded in Q2 2024.
- In the past 5 years, Therapeutics' Cash & Equivalents ranged from a high of $91.5 million in Q1 2020 and a low of $20.2 million during Q3 2020
- Over the past 5 years, Therapeutics' median Cash & Equivalents value was $38.9 million (recorded in 2022), while the average stood at $43.9 million.
- Within the past 5 years, the most significant YoY rise in Therapeutics' Cash & Equivalents was 19775.18% (2021), while the steepest drop was 7299.22% (2021).
- Over the past 5 years, Therapeutics' Cash & Equivalents (Quarter) stood at $24.9 million in 2020, then dropped by 3.58% to $24.0 million in 2021, then skyrocketed by 62.09% to $38.9 million in 2022, then increased by 21.91% to $47.5 million in 2023, then fell by 20.17% to $37.9 million in 2024.
- Its last three reported values are $37.9 million in Q3 2024, $37.1 million for Q2 2024, and $45.3 million during Q1 2024.